NR3C2 and diabetic kidney disease: In a distinct mechanism, a recent study published in JCI Insight revealed that MR antagonists have the capacity to reduce urinary protein excretion and impede DKD progression by safeguarding the glomerular endothelial glycocalyx (GEnGlx) (183).